Media coverage about Ophthotech (NASDAQ:OPHT) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ophthotech earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.0204595408817 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern’s analysis:
A number of equities analysts recently commented on the stock. TheStreet downgraded shares of Ophthotech from a “c” rating to a “d+” rating in a research note on Friday, March 2nd. ValuEngine downgraded shares of Ophthotech from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. JPMorgan Chase downgraded shares of Ophthotech from a “neutral” rating to an “underweight” rating in a research note on Monday, March 19th. Finally, Zacks Investment Research downgraded shares of Ophthotech from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 7th. One analyst has rated the stock with a sell rating and three have given a hold rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $3.63.
OPHT remained flat at $$2.60 on Tuesday. 59,797 shares of the company were exchanged, compared to its average volume of 281,677. Ophthotech has a 52-week low of $2.24 and a 52-week high of $3.60. The stock has a market capitalization of $95.18, a PE ratio of 0.82 and a beta of 1.36.
Ophthotech (NASDAQ:OPHT) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.32. Ophthotech had a net margin of 26.69% and a negative return on equity of 230.07%. During the same period in the previous year, the firm earned ($1.86) earnings per share. analysts anticipate that Ophthotech will post -1.71 EPS for the current year.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Ophthotech (OPHT) Stock Price” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/24/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-ophthotech-opht-stock-price.html.
Ophthotech Company Profile
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD).
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.